BMS beats analysts' Q2 projections

Despite competition coming in from generics, sales of cancer treatment Revlimid have fared better than anticipated in Bristol Myers Squibb’s second quarter.

Photo: Bristol Myers Squibb / PR

US-based pharmaceutical giant Bristol Myers Squibb has outperformed sales expectations in the second quarter of the year, partially driven by sales of Revlimid, a cancer drug, dropping less than what was guided for due to competition from generics.

Falling on the favorable side of the projected USD 11.4bn, total revenue is up 1.6% in Q2 to USD 11.89bn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs